RegenXBio (RGNX) AI Stock Analysis

• Market Cap: $458.03M
• Dividend Yield: N/A
• Average Volume (3M): 721.08K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.15
• Revenue Growth: 80.70%
• EPS Growth: 46.66%
• Country: US
• Employees: 353
• Sector: Healthcare
• Sector Strength: 37
• Industry: Biotechnology
• EPS (TTM): 0.12
• Shares Outstanding: 50,388,695
• 10 Day Avg. Volume: 531,011
• 30 Day Avg. Volume: 721,076
• PEG Ratio: -0.08
• Price to Book (P/B): 1.55
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -4.81
• Enterprise Value/Market Cap: 0.80
• Enterprise Value/Revenue: 0.88
• Enterprise Value/Gross Profit: 3.04
• Enterprise Value/Ebitda: -0.48
• 1Y Price Target: $31.43
• Price Target Upside: 244.25% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 9

• Rating: 54 Neutral
• Price Target: $8.50 ▼(-6.90%Downside)

RegenXBio's overall score reflects significant financial challenges and valuation concerns, partly offset by positive developments in its clinical pipeline and strategic partnerships. The recent royalty monetization deal adds financial stability, but regulatory uncertainties and competitive pressures remain key risks.

Positive Factors

Regulatory Approval

Interactions with regulatory agency have been positive, with accelerated approval still remaining on the table.

Safety Profile

RGNX has a clean safety profile with no serious adverse events reported in the 13 patients treated thus far.

Trial Enrollment

Enrollment in the pivotal portion of AFFINITY DUCHENNE has surpassed 50%, indicating strong interest in the trial.

Negative Factors

Market Performance

Shares are down over 10% despite functional benefit optically superior to Elevidys, as bears argue small number of patients and optical regression in NSAA make differentiation versus SRPT unclear.

Market Sentiment

Recent events are expected to weigh on sentiment for gene therapy stocks across the S&P 600 Health Care Index.

Regulatory Concerns

There is an expectation that RGNX bears may argue regulators could become more conservative on future DMD gene therapies.

RegenXBio Business Overview & Revenue Model

Company Description

RegenXBio Inc. is a biotechnology company specializing in the development, commercialization, and licensing of gene therapy products. It operates in the biopharmaceutical sector with a focus on leveraging its proprietary NAV Technology Platform to develop transformative treatments for retinal, neurodegenerative, and metabolic diseases. RegenXBio's core products and services include a pipeline of internally developed gene therapy candidates and partnerships with other biopharmaceutical companies to advance novel therapeutic solutions.

How the Company Makes Money

RegenXBio makes money through a combination of product development, licensing agreements, and strategic partnerships. A significant portion of the company's revenue is derived from licensing its NAV Technology Platform to other biotech and pharmaceutical companies, allowing them to develop their own gene therapy products. These licensing agreements often include upfront payments, milestone payments based on the achievement of specific development or regulatory goals, and royalties on future sales of licensed products. Additionally, RegenXBio generates revenue through collaborations and partnerships that involve co-development or co-commercialization of therapeutic candidates, sharing both the risks and potential rewards of product development. The company's revenue model is heavily dependent on the success of its gene therapy candidates, both those developed internally and those advanced through partnerships.

RegenXBio Financial Statement Overview

Summary

RegenXBio faces significant financial challenges with consistent losses and negative cash flows. While there is a strong cash position and slight improvement in free cash flow, overall financial health remains weak.

Income Statement

RegenXBio has experienced fluctuating revenue with a significant decline from 2021 to 2024, followed by a slight recovery in TTM. The company has consistently reported negative EBIT and net income, indicating ongoing operational challenges. Gross profit margins have remained relatively stable, but the net profit margin is negative, reflecting persistent losses.

Balance Sheet

The company maintains a moderate debt-to-equity ratio, suggesting manageable leverage. However, stockholders' equity has decreased over time, indicating potential financial strain. The equity ratio has also declined, reflecting reduced financial stability. Despite these challenges, the company has maintained a strong cash position relative to its debt.

Cash Flow

RegenXBio has faced negative operating and free cash flows, highlighting cash flow challenges. However, there has been a positive trend in free cash flow growth in the TTM period, indicating some improvement. The operating cash flow to net income ratio is unfavorable, reflecting cash flow inefficiencies.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	83.33M	90.24M	112.72M	470.35M	154.57M
Gross Profit	49.76M	53.03M	58.18M	418.51M	118.85M
EBITDA	-198.23M	-239.46M	-244.24M	169.54M	-96.83M
Net Income	-227.10M	-263.49M	-280.32M	127.84M	-111.25M
Balance Sheet
Total Assets	465.99M	573.97M	833.27M	1.11B	708.16M
Cash, Cash Equivalents and Short-Term Investments	234.69M	275.26M	364.64M	457.44M	475.74M
Total Debt	82.03M	89.29M	94.80M	86.68M	72.65M
Total Liabilities	206.34M	262.23M	317.07M	349.61M	330.41M
Stockholders Equity	259.65M	311.74M	516.20M	764.30M	377.75M
Cash Flow
Free Cash Flow	-175.56M	-228.37M	-238.21M	134.70M	-80.93M
Operating Cash Flow	-173.13M	-218.41M	-207.49M	218.88M	-54.06M
Investing Cash Flow	103.45M	190.94M	-11.93M	-406.64M	122.76M
Financing Cash Flow	92.68M	-34.97M	-28.84M	195.25M	200.21M

RegenXBio Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 9.13
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RGNX, the sentiment is Positive. The current price of 9.13 is above the 20-day moving average (MA) of 8.63, above the 50-day MA of 8.97, and above the 200-day MA of 8.42, indicating a bullish trend. The MACD of -0.01 indicates Negative momentum. The RSI at 55.09 is Neutral, neither overbought nor oversold. The STOCH value of 77.06 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for RGNX.

RegenXBio Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AMLX	57 Neutral	$739.87M	―	-83.24%	―	-100.32%	-197.69%
RGNX	54 Neutral	$458.03M	―	-47.44%	―	80.70%	46.66%
Sector *	52 Neutral	$7.61B	0.10	-63.03%	2.08%	16.34%	0.32%
VERV	52 Neutral	$992.16M	―	-34.26%	―	271.44%	26.65%
TSHA	50 Neutral	$677.36M	―	-159.34%	―	-48.97%	69.32%
IVA	47 Neutral	$451.65M	―	344.74%	―	-47.32%	-26.67%
ERAS	34 Underperform	$484.42M	―	-45.82%	―	―	10.38%

RegenXBio Corporate Events

RegenXBio Holds 2025 Annual Stockholders Meeting

At REGENXBIO Inc.’s 2025 Annual Meeting of Stockholders held on May 30, 2025, several key proposals were voted on. Four individuals were elected as Class I directors to serve until 2028, and PricewaterhouseCoopers LLP was ratified as the independent public accounting firm for the year. Additionally, stockholders approved the executive compensation plan and decided to hold annual advisory votes on this matter. The 2025 Equity Incentive Plan was also approved.

The most recent analyst rating on (RGNX) stock is a Buy with a $39.00 price target. To see the full list of analyst forecasts on RegenXBio stock, see the RGNX Stock Forecast page.

RegenXBio Secures $250M Royalty Monetization Deal

On May 16, 2025, REGENXBIO Inc. announced a strategic royalty monetization agreement with HealthCare Royalty Management, LLC, securing up to $250 million in non-dilutive funding through a limited recourse royalty bond. This agreement provides immediate capital of $150 million, extending the company’s cash runway into early 2027 and supporting its late-stage gene therapy programs. The deal allows REGENXBIO to leverage anticipated royalties from products like ZOLGENSMA® and potential future milestones, positioning the company to accelerate commercial preparations and maintain its leadership in gene therapy.

The most recent analyst rating on (RGNX) stock is a Buy with a $39.00 price target. To see the full list of analyst forecasts on RegenXBio stock, see the RGNX Stock Forecast page.